
Releases
Acousia Therapeutics Reports Positive Phase 2a Results for ACOU085
In a study of testicular cancer patients undergoing chemotherapy, the experimental drug ACOU085 successfully mitigated hearing loss caused by cisplatin. The Phase 2a PROHEAR trial indicates that the small molecule, administered via transtympanic injection, provides a protective effect against the damage typically inflicted on the inner ear during standard cancer treatments.























